证券代码：301235 证券简称：华康医疗 公告编号：2023-067 武汉华康世纪医疗股份有限公司 关于调整公司向不特定对象发行可转换公司债券方案及相关文 件修订说明的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 武汉华康世纪医疗股份有限公司（以下简称"公司"）于 2023 年 4 月 21 日召开第二届董事会第五次会议及第二届监事会第五次会议，审议通过了关于公 司向不特定对象发行可转换公司债券（以下简称"本次发行"）的相关议案。具 体内容详见公司于 2023 年 4月 25 日在中国证监会指定的创业板信息披露网站巨 潮资讯网（www.cninfo.com.cn）披露的相关公告。 公司于 2023 年 8月 16 日召开了第二届董事会第八次会议及第二届监事会第 八次会议，审议通过了《关于调整公司向不特定对象发行可转换公司债券方案的 议案》等相关议案。根据相关法律法规及规范性文件的要求，为确保公司本次向 不特定对象发行可转换公司债券的顺利进行，公司对本次向不特定对象发行可转 换公司债券发行规模及募集资金用途进行调整，将本次发行募集资金总额由不超 过 8 ...

证券代码：301235 证券简称：华康医疗 公告编号：2023-070 武汉华康世纪医疗股份有限公司 关于向不特定对象发行可转换公司债券摊薄即期回报 及采取填补措施和相关主体承诺（修订稿）的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 武汉华康世纪医疗股份有限公司（以下简称"公司"）拟向不特定对象发行可转换 公司债券（以下简称"本次发行"）。根据《国务院办公厅关于进一步加强资本市场中小 投资者合法权益保护工作的意见》（国办发[2013]110 号）《国务院关于进一步促进资本 市场健康发展的若干意见》（国发[2014]17 号）和《关于首发及再融资、重大资产重组 摊薄即期回报有关事项的指导意见》（中国证券监督管理委员会[2015]31 号）等规定， 为保障中小投资者利益，公司就本次发行摊薄即期回报对主要财务指标的影响进行了认 真的分析，并就采取的填补回报措施说明如下： 一、本次发行摊薄即期回报对主要财务指标的影响测算 （一）假设前提 1、假设宏观经济环境、公司所处行业情况及公司经营环境等方面没有发生重大不 利变化； 2、假设本次发行于 2023 年 12 ...

股票代码：301235 股票简称：华康医疗 武汉华康世纪医疗股份有限公司 Wuhan Huakang Century Medical Co., Ltd. （武汉东湖新技术开发区光谷大道 77 号光谷金融港 B4 栋 8-9 层） 向不特定对象发行可转换公司债券 募集资金使用的可行性分析报告 （修订稿） 二〇二三年八月 武汉华康世纪医疗股份有限公司 关于本次募集资金使用的可行性分析报告 武汉华康世纪医疗股份有限公司 | 项目名称 | | 实施主体 | 总投资额 | 拟以募集资 金额投入 | | --- | --- | --- | --- | --- | | 智慧医疗物联网云平台升级项目 | | 华康医疗 | 5,026.63 | 4,903.22 | | 洁 净 医疗专 项 工 程建设 | 光谷人民医院医疗专项设 武汉市第一医院突发公共 应急救治中心项目 | 华康医疗 | 16,983.96 | 14,000.00 | | 计施工总承包项目 | | | | | | 卫生事件中西医结合临床 | | | 3,281.82 | 3,000.00 | | 项目 | 上海交通大学医学院浦东 校区工程（标段二）科研 | | ...

武汉华康世纪医疗股份有限公司 关于特定股东减持股份数量过半的进展公告 公司特定股东深圳市达晨创丰股权投资企业（有限合伙）保证向本公司提供的信息内 容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 武汉华康世纪医疗股份有限公司(以下简称"公司"）于2023年6月15日在巨潮资 讯网披露了《关于特定股东减持股份的预披露公告》（公告编号：2023-053）。公司 股东深圳市达晨创丰股权投资企业（有限合伙）（以下简称"达晨创丰"）拟通过集 中竞价、大宗交易的方式减持公司股份不超过792,000股，拟减持比例不超过公司总股 本的0.7500%。其中，通过集中竞价方式减持的，自减持计划公告之日起15个交易日后 6个月内进行；通过大宗交易方式减持的，自减持计划公告之日起3个交易日后的6个月 内进行（如遇派息、送股、转增股本、配股等除权除息事项，上述拟减持股份数量将 相应进行调整，但减持股份占公司总股本的比例不变）。 公司于今日收到股东达晨创丰出具的《关于股份减持计划实施进展告知函》，截 至2023年8月10日，达晨创丰本次股份减持计划减持数量过半， ...

证券代码：301235 证券简称：华康医疗 武汉华康世纪医疗股份有限公司 投资者关系活动记录表 编号：2023-002 | --- | --- | --- | |------------------|---------------|-------------| | 投资者关系活动类 | ☐特定对象调研 | ☐分析师会议 | | 别 | ☐媒体采访 | 业绩说明会 | | | ☐新闻发布会 | ☐路演活动 | | | ☐现场参观 | | | | ☐ | | 参与单位名称及 线上参与公司2022年度网上业绩说明会的投资者 人员姓名 时间 2023年05月15日 15:00-17:00 地点 价值在线（https://www.ir-online.cn/）网络互动 董事长 谭平涛先生 总经理 谢新强先生 独立董事 郭孟焕女士 上市公司接待人员 姓名 董事会秘书、副总经理 彭沾先生 财务负责人 张英超女士 保荐代表人 李鹏程先生 | --- | --- | |----------------|------------------------------------------------------| | | 1.1季 ...

证券代码：301235 证券简称：华康医疗 武汉华康世纪医疗股份有限公司 投资者关系活动记录表 | --- | --- | |------------------------------------|-----------------------------------------------------------------------| | | 特定对象调研 | | 投 资 者 关系 活 | □媒体采访 | | 动类别 | □新闻发布会 | | | 现场参观 | | | 其他（电话会议） | | | 歌斐诺宝 胡昌杰；明世伙伴基金 | | | 嘉实基金 张鑫荔；民生通惠 | | | 恒宇投资 张宇 田春燕 | | | 盛 劳亭嘉；汇添富基金 | | | 黎晓楠 蒋晶；贵诚信托 | | | 私募 杨莹； | | 参 与 单 位名 称 | Wendy WANG；亿能投资 | | 及人员姓名 | 鲁春娥；源乘投资 | | | 文瀚；进门财经 | | | 万宏源 王子欣；创金合信基金 | | | | | | 天时开元股权基金 | | | 冶；富国基金 | | | 在存；严娟；莫珊；张萌 | | 时间 | 202 ...

证券代码：301235 证券简称：华康医疗 公告编号：2023-044 武汉华康世纪医疗股份有限公司 关于举办2022年度网上业绩说明会的公告 武汉华康世纪医疗股份有限公司（以下简称"公司"）已于 2023 年 4 月 25 日在巨潮资讯网上披露了《2022 年年度报告》及《2022 年年度报告摘要》。为 便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司定于 2023 年 05 月 15 日（星期一）15:00-17:00 在"价值在线"（www.ir-online.cn） 举办公司 2022 年度网上业绩说明会，与投资者进行沟通和交流，广泛听取投资 者的意见和建议。 一、说明会召开的时间、地点和方式 会议召开时间：2023 年 05 月 15 日（星期一）15:00-17:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 二、参加人员 出席本次年度网上业绩说明会的人员有：董事长谭平涛先生，总经理谢新强 先生，独立董事郭孟焕女士，董事会秘书、副总经理彭沾先生，财务负责人张英 超女士，保荐代表人李鹏程先生。 三、投资者参加方式 投资者可于 2023 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 240,206,327.57, representing an increase of 82.92% compared to CNY 131,319,672.55 in the same period last year[4]. - The net loss attributable to shareholders for Q1 2023 was CNY -17,309,522.74, a decrease of 101.66% from CNY -8,583,730.95 in Q1 2022[4]. - Net profit for Q1 2023 is -17,309,522.74 RMB, a decrease of 101.66% compared to Q1 2022[14]. - The basic and diluted earnings per share were both -¥0.16, worsening from -¥0.09 in the previous period[28]. - Total operating revenue for the current period reached ¥240,206,327.57, a significant increase from ¥131,319,672.55 in the previous period, representing an increase of approximately 83%[26]. - The net loss for the current period was ¥17,309,522.74, compared to a net loss of ¥8,583,730.95 in the previous period, reflecting an increase in losses of approximately 102%[28]. Cash Flow - The net cash flow from operating activities was CNY -205,749,592.42, a decline of 6.47% compared to CNY -193,250,545.06 in the previous year[4]. - Cash flow from operating activities showed a net outflow of ¥205,749,592.42, compared to a net outflow of ¥193,250,545.06 in the previous period[30]. - Investment activities generated a net cash flow of 404,394,431.90 RMB, a 178.15% increase from the previous year[15]. - Cash flow from investing activities generated a net inflow of ¥404,394,431.90, contrasting with a net outflow of ¥517,453,534.57 in the previous period[30]. - Financing activities resulted in a net cash flow of 97,149,635.24 RMB, down 88.25% from the previous year[15]. - Cash flow from financing activities resulted in a net inflow of ¥97,149,635.24, down from ¥826,578,481.17 in the previous period[32]. - The ending cash and cash equivalents balance was ¥429,125,286.77, an increase from ¥305,091,543.28 in the previous period[32]. - The company's cash and cash equivalents increased by 120.10% to CNY 555,284,119.25, primarily due to the maturity of idle raised funds[11]. Assets and Liabilities - As of the end of Q1 2023, the company had a total asset value of CNY 2,319,324,309.61, a decrease of 2.14% from CNY 2,369,993,275.66 at the end of the previous year[4]. - The total current assets as of March 31, 2023, amounted to CNY 2,086,325,371.35, a decrease from CNY 2,133,466,006.70 at the beginning of the year[21]. - Total liabilities decreased to CNY 670,385,913.93 from CNY 717,195,126.15, a reduction of about 6.5%[23]. - The total assets as of March 31, 2023, were CNY 2,319,324,309.61, down from CNY 2,369,993,275.66 at the beginning of the year[23]. - The company's equity attributable to shareholders decreased to CNY 1,648,938,395.68 from CNY 1,652,798,149.51, a decline of approximately 0.2%[25]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 9,691[14]. - Major shareholder, Tan Pingtao, holds 44.23% of the shares, totaling 46,708,990 shares[14]. - Sun Life Insurance Company holds 6.50% of the shares, totaling 6,864,046 shares[14]. - The company has a total of 10 major shareholders, with varying percentages of ownership[16]. - The company has a total of 80,558,504 shares under lock-up agreements, with 25,312,294 shares released during the period[19]. Research and Development - Research and development expenses increased by 129.32% to CNY 23,300,468.90 compared to CNY 10,160,474.31 in Q1 2022[12]. - The company is focusing on R&D investments, which have increased during the reporting period[14]. - Research and development expenses for the current period were ¥23,300,468.90, significantly higher than ¥10,160,474.31 in the previous period, marking an increase of approximately 129%[26]. Operational Expenses - Operating expenses increased significantly, contributing to the net loss[14]. - Sales expenses rose by 40.04% to CNY 33,931,560.78, driven by an increase in sales personnel and marketing costs[12]. - Total operating costs amounted to ¥267,516,174.95, up from ¥146,259,169.33, indicating a rise of about 83%[26]. Future Outlook - The company plans to continue its market expansion and product development strategies in the upcoming quarters[22]. - The company reported a significant increase in cash flow, which will support future investments and operational needs[21].

Financial Performance - The company's operating revenue for 2022 was approximately ¥1.19 billion, representing a 38.12% increase compared to ¥860.81 million in 2021[32]. - The net profit attributable to shareholders for 2022 was approximately ¥102.49 million, a 25.97% increase from ¥81.36 million in 2021[32]. - The cash flow from operating activities showed a significant decline, with a net outflow of approximately ¥342.10 million in 2022 compared to a net inflow of ¥44.59 million in 2021, marking an 867.16% decrease[32]. - The total assets at the end of 2022 reached approximately ¥2.37 billion, a 91.32% increase from ¥1.24 billion at the end of 2021[32]. - The company's net assets attributable to shareholders increased by 179.16% to approximately ¥1.65 billion at the end of 2022, up from ¥592.06 million at the end of 2021[32]. - The basic earnings per share for 2022 was ¥0.99, a decrease of 3.88% from ¥1.03 in 2021[32]. - The company reported a weighted average return on equity of 6.76% for 2022, down from 14.76% in 2021, indicating a decline of 8.00%[32]. - The company achieved a revenue of 1.1889 billion yuan in 2022, representing a year-on-year growth of 38.12%[60]. - The net profit attributable to shareholders for 2022 was 102.49 million yuan, a 25.97% increase compared to the previous year[60]. - The company's total assets grew by 91.32% to 2,369.99 million yuan by the end of the reporting period[60]. Cash Flow and Investments - The net cash flow from operating activities decreased by 867.16% year-on-year, primarily due to increased inventory and accounts receivable amid economic downturn and business expansion[115]. - The net cash flow from investment activities decreased by 7,003.49% year-on-year, mainly due to the use of idle raised funds for purchasing financial products and construction of investment projects[116]. - The net cash flow from financing activities increased by 1,323.19% year-on-year, primarily due to funds received from the IPO[117]. - Total cash inflow from operating activities was 844.72 million yuan, while total cash outflow was 1,186.81 million yuan, resulting in a net cash outflow of 342.10 million yuan[115]. - The company's total assets included cash and cash equivalents of 252.29 million yuan, accounting for 10.65% of total assets, a decrease of 8.37% from the previous year[121]. - The company raised a total of RMB 103,752.00 million through the issuance of 26.4 million shares at RMB 39.30 per share, with a net amount of RMB 94,950.28 million after deducting issuance costs of RMB 8,801.72 million[133]. - As of December 31, 2022, the company has utilized RMB 39,542.50 million of the raised funds, leaving a balance of RMB 55,407.78 million in unutilized funds[134]. Market and Business Expansion - The company plans to continue expanding its market presence and developing new technologies in the medical purification system sector[42]. - The company is focused on expanding its market presence and enhancing its product offerings through research and development[128]. - The company is exploring new strategies for market expansion and potential mergers and acquisitions to strengthen its competitive position[154]. - The company is actively investing in R&D for new technologies, with a budget allocation of approximately $10 million for the next year[158]. - The company is expanding its market presence, targeting an increase in market share by 10% in the next fiscal year[156]. - The overall market expansion strategy includes entering three new regional markets by the end of the fiscal year[156]. Research and Development - The company has developed a range of patented technologies and integrated information systems to enhance its market competitiveness[7]. - The company has 4 invention patents and 141 utility model patents as of December 31, 2022, showcasing its strong R&D capabilities[94]. - The company completed several key R&D projects, including an intelligent gas system and a remote alarm control system, enhancing its competitive edge in the medical industry[113]. - The company aims to enhance its industry reputation and competitiveness through innovative R&D initiatives and strategic expansions[113]. - The number of R&D personnel increased by 44.74% from 152 in 2021 to 220 in 2022, indicating a significant expansion in the R&D team[114]. Corporate Governance - The company is committed to enhancing its governance level through regular reviews and approvals of major decisions by the board and shareholders[169]. - The company maintains independence from its controlling shareholders, ensuring that its operations and decision-making processes are not influenced by external entities[164]. - The board of directors is supported by specialized committees to enhance decision-making efficiency and professionalism[165]. - The company adheres to strict information disclosure regulations, ensuring timely and accurate communication with investors[167]. - The company is actively engaging in corporate governance practices to ensure compliance and transparency[182]. Operational Efficiency - The company emphasizes cost management throughout the bidding and project execution phases, effectively reducing operational cost risks[84]. - The company is focused on improving the quality of medical services through the establishment of specialized medical institutions and diagnostic centers[46]. - The company is committed to improving its corporate image and operational management to support its rapid development and technological advancements[151]. - The company aims to improve project management efficiency and profitability through refined management practices and strict quality control measures[149]. Strategic Partnerships and Collaborations - The company has formed strategic partnerships with renowned design institutes, increasing its market influence and order quality[88]. - The company is committed to fostering international cooperation in technology innovation and resource sharing in the healthcare sector[43]. - The company is encouraged to strengthen cooperation with national laboratories and research institutions to enhance innovation in the biomedicine field[45]. Social Responsibility and Community Engagement - The company actively fulfills its corporate social responsibility, balancing the interests of shareholders, employees, and society to promote sustainable development[168]. - The company aims to enhance the infrastructure of medical institutions, focusing on building national and regional medical centers, particularly in under-resourced areas[43].